SCH-12679 MALEATE structure
|
Common Name | SCH-12679 MALEATE | ||
|---|---|---|---|---|
| CAS Number | 39624-66-3 | Molecular Weight | 412.45600 | |
| Density | N/A | Boiling Point | 416.8ºC at 760 mmHg | |
| Molecular Formula | C23H26NO6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 137.5ºC | |
|
Behavioural effects of psychoactive drugs on agonistic behaviour of male territorial rats (resident-intruder model).
Prog. Clin. Biol. Res. 167 , 137-56, (1984)
|
|
|
Effects of the phenethylamine derivatives, BL-3912, fenfluramine, and Sch-12679, in rats trained with LSD as a discriminative stimulus.
Psychopharmacology 68(2) , 159-62, (1980) Six rats were trained to discriminate the effects of LSD (100 micrograms/kg) and saline in a two-lever choice task. They were then tested with each of three phenethylamine derivatives, BL-3912 (2,5-dimethoxy-4-methyl-alpha-ethyl-phenethylamine), fenfluramine ... |
|
|
Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
J. Pharmacol. Exp. Ther. 252 , 558-567, (1990) The benzazepine compound SCH-12679 has been shown to have clinical efficacy against aggressive behavior in mentally deficient patients. The purpose of the present investigation was to evaluate the potential mechanism of action of SCH-12679. Because of the str... |
|
|
The behavioral pharmacology of Sch 12679. A new psychoactive agent.
Psychopharmacology 36 , 281-290, (1974)
|
|
|
Evidence that lack of brain dopamine during development can increase the susceptibility for aggression and self-injurious behavior by influencing D1-dopamine receptor function.
Prog. Neuropsychopharmacol. Biol. Psychiatry 14 Suppl , S65-80, (1990) 1. Lesch-Nyhan disease has a defined neurological lesion that is accompanied by abnormal motor function, aggression and self-injurious behavior. 2. The dopamine deficiency in Lesch-Nyhan disease has been modelled by destroying dopamine-containing neurons in n... |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved